Exscientia

Recursion and Exscientia received shareholder approval for their proposed combination, expected to close on November 20, 2024. Recursion plans an update call after the close, to be broadcasted on X, LinkedIn, and YouTube. Chris Gibson, Recursion's CEO, expressed enthusiasm for combining Recursion's biological and chemical capabilities with Exscientia's molecular design and automated chemistry to accelerate drug discovery.

Save time by focusing on key insights.

AI in healthcare is booming, with Mayo Clinic and Elon Musk's Grok AI leading the charge. Major tech companies like Nvidia, Google, and Microsoft showcased healthcare AI tools at the HLTH conference. Avant Technologies and Ainnova Tech formed a joint venture to advance early disease detection using AI, targeting a $67.4 billion market by 2027. Other companies like Recursion Pharmaceuticals, Exscientia, Absci Corporation, and Twist Bioscience are also making strides in AI-driven healthcare innovations.

Rallybio reports Q3 2024 financials, $75.1M cash runway into mid-2026, and CTA approvals for RLYB212 Phase 2 trial, set to initiate screening in 4Q 2024.

The 'golden age' of medicine sees breakthroughs in mRNA, ADCs, and microbiome therapies, with Casgevy's approval marking a CRISPR milestone. Oncology and immunology dominate drug sales, while obesity, Alzheimer’s, and CVD treatments gain momentum. Precision medicine and cost optimization are priorities, leveraging AI, blockchain, and IoMT. Health system reforms in the U.S. and EU introduce stricter pricing regulations, challenging drug manufacturers.

TVM Capital Life Science hosts AI-focused sessions at BIO-Europe 2024, discussing AI's impact on biopharma, drug discovery, and diagnostics.

The AI in biotechnology market is dominated by cloud-based solutions due to scalability and reduced costs. Research institutes and labs are expected to grow fastest, leveraging AI for data analysis and virtual models. North America leads in market share, driven by substantial funding and AI integration across sectors. Key players include NVIDIA, Illumina, and Exscientia, focusing on AI applications in healthcare and drug development.

The global AI in Biotechnology market is expected to grow from USD 3.23 billion in 2024 to USD 7.75 billion by 2029, driven by cross-industry collaborations, AI-powered biomarker discovery, and AI-CRISPR synergy. Key players include NVIDIA, Illumina, Exscientia, and others, who use strategies like partnerships and product launches to dominate the market. Challenges include fragmented regulations and AI infrastructure limitations.

AI in biotechnology market to reach USD 7.75 billion by 2029, driven by personalized medicine, supply chain optimization, and clinical trial innovations. End-to-end solutions and cloud-based deployments lead growth. Asia Pacific expected to grow fastest due to government support.

Cellino Biotech appoints Chris Gibson to its Board of Directors. Gibson, Recursion's CEO, brings AI-driven drug discovery experience. Cellino aims to scale autonomous biomanufacturing for personalized regenerative medicines.